mk 0852 has been researched along with Myocardial Infarction in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rossi, G | 1 |
| Bogaty, P; Kingma, JG; Plante, S | 1 |
2 other study(ies) available for mk 0852 and Myocardial Infarction
| Article | Year |
|---|---|
[Superaspirin in the platelet aggregation inhibitor therapy].
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Integrins; Myocardial Infarction; Oligopeptides; Peptides, Cyclic; Platelet Aggregation Inhibitors; Recurrence; Sulfoxides; Thiazolidines; Time Factors; Tyrosine | 1997 |
Platelet GPIIb/IIIa receptor blockade reduces infarct size in a canine model of ischemia-reperfusion.
Topics: Animals; Coronary Circulation; Disease Models, Animal; Dogs; Female; Flow Cytometry; Heart; Hemodynamics; Hyperemia; Male; Myocardial Contraction; Myocardial Infarction; Myocardial Reperfusion Injury; Oligopeptides; Peptides, Cyclic; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thiazolidines | 2000 |